Cargando…
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Milan
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047372/ https://www.ncbi.nlm.nih.gov/pubmed/35484489 http://dx.doi.org/10.1186/s10194-022-01422-y |
| _version_ | 1784695711432966144 |
|---|---|
| author | Barbanti, Piero Egeo, Gabriella Aurilia, Cinzia d’Onofrio, Florindo Albanese, Maria Cetta, Ilaria Di Fiore, Paola Zucco, Maurizio Filippi, Massimo Bono, Francesco Altamura, Claudia Proietti, Stefania Bonassi, Stefano Vernieri, Fabrizio |
| author_facet | Barbanti, Piero Egeo, Gabriella Aurilia, Cinzia d’Onofrio, Florindo Albanese, Maria Cetta, Ilaria Di Fiore, Paola Zucco, Maurizio Filippi, Massimo Bono, Francesco Altamura, Claudia Proietti, Stefania Bonassi, Stefano Vernieri, Fabrizio |
| author_sort | Barbanti, Piero |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9047372 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Milan |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90473722022-04-29 Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) Barbanti, Piero Egeo, Gabriella Aurilia, Cinzia d’Onofrio, Florindo Albanese, Maria Cetta, Ilaria Di Fiore, Paola Zucco, Maurizio Filippi, Massimo Bono, Francesco Altamura, Claudia Proietti, Stefania Bonassi, Stefano Vernieri, Fabrizio J Headache Pain Correction Springer Milan 2022-04-28 /pmc/articles/PMC9047372/ /pubmed/35484489 http://dx.doi.org/10.1186/s10194-022-01422-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Barbanti, Piero Egeo, Gabriella Aurilia, Cinzia d’Onofrio, Florindo Albanese, Maria Cetta, Ilaria Di Fiore, Paola Zucco, Maurizio Filippi, Massimo Bono, Francesco Altamura, Claudia Proietti, Stefania Bonassi, Stefano Vernieri, Fabrizio Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) |
| title | Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) |
| title_full | Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) |
| title_fullStr | Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) |
| title_full_unstemmed | Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) |
| title_short | Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) |
| title_sort | correction to: fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the friend study) |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047372/ https://www.ncbi.nlm.nih.gov/pubmed/35484489 http://dx.doi.org/10.1186/s10194-022-01422-y |
| work_keys_str_mv | AT barbantipiero correctiontofremanezumabinthepreventionofhighfrequencyepisodicandchronicmigrainea12weekmulticenterreallifecohortstudythefriendstudy AT egeogabriella correctiontofremanezumabinthepreventionofhighfrequencyepisodicandchronicmigrainea12weekmulticenterreallifecohortstudythefriendstudy AT auriliacinzia correctiontofremanezumabinthepreventionofhighfrequencyepisodicandchronicmigrainea12weekmulticenterreallifecohortstudythefriendstudy AT donofrioflorindo correctiontofremanezumabinthepreventionofhighfrequencyepisodicandchronicmigrainea12weekmulticenterreallifecohortstudythefriendstudy AT albanesemaria correctiontofremanezumabinthepreventionofhighfrequencyepisodicandchronicmigrainea12weekmulticenterreallifecohortstudythefriendstudy AT cettailaria correctiontofremanezumabinthepreventionofhighfrequencyepisodicandchronicmigrainea12weekmulticenterreallifecohortstudythefriendstudy AT difiorepaola correctiontofremanezumabinthepreventionofhighfrequencyepisodicandchronicmigrainea12weekmulticenterreallifecohortstudythefriendstudy AT zuccomaurizio correctiontofremanezumabinthepreventionofhighfrequencyepisodicandchronicmigrainea12weekmulticenterreallifecohortstudythefriendstudy AT filippimassimo correctiontofremanezumabinthepreventionofhighfrequencyepisodicandchronicmigrainea12weekmulticenterreallifecohortstudythefriendstudy AT bonofrancesco correctiontofremanezumabinthepreventionofhighfrequencyepisodicandchronicmigrainea12weekmulticenterreallifecohortstudythefriendstudy AT altamuraclaudia correctiontofremanezumabinthepreventionofhighfrequencyepisodicandchronicmigrainea12weekmulticenterreallifecohortstudythefriendstudy AT proiettistefania correctiontofremanezumabinthepreventionofhighfrequencyepisodicandchronicmigrainea12weekmulticenterreallifecohortstudythefriendstudy AT bonassistefano correctiontofremanezumabinthepreventionofhighfrequencyepisodicandchronicmigrainea12weekmulticenterreallifecohortstudythefriendstudy AT vernierifabrizio correctiontofremanezumabinthepreventionofhighfrequencyepisodicandchronicmigrainea12weekmulticenterreallifecohortstudythefriendstudy AT correctiontofremanezumabinthepreventionofhighfrequencyepisodicandchronicmigrainea12weekmulticenterreallifecohortstudythefriendstudy |